Healthcare provider profile · identity verified

Elian Daniel Paiuk, MD

Family Practice · PANORAMA CITY, CA · NPI 1841382272

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1081	400
Metformin Hcl	Metformin Hcl	459	168
Lisinopril	Lisinopril	430	152
Amlodipine Besylate	Amlodipine Besylate	387	151
Rosuvastatin Calcium	Rosuvastatin Calcium	372	145
Losartan Potassium	Losartan Potassium	365	139
Omeprazole	Omeprazole	284	110
Levothyroxine Sodium	Levothyroxine Sodium	254	83
Glipizide	Glipizide	243	94
Hydrochlorothiazide	Hydrochlorothiazide	243	91
Jardiance	Empagliflozin	184	70
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	165	63
Tamsulosin Hcl	Tamsulosin Hcl	154	57
Meloxicam	Meloxicam	132	70
Alendronate Sodium	Alendronate Sodium	125	53
Hydrocortisone	Hydrocortisone	125	53
Ibuprofen	Ibuprofen	118	42
Potassium Chloride	Potassium Chloride	118	61
Gabapentin	Gabapentin	114	58
Terazosin Hcl	Terazosin Hcl	99	35
Atenolol	Atenolol	92	34
Lorazepam	Lorazepam	91	27
Simvastatin	Simvastatin	91	30
Metoprolol Tartrate	Metoprolol Tartrate	89	34
Humulin N	Insulin Nph Human Isophane	88	31
Hydralazine Hcl	Hydralazine Hcl	83	33
Triamcinolone Acetonide	Triamcinolone Acetonide	83	44
Pantoprazole Sodium	Pantoprazole Sodium	80	34
Humulin N Kwikpen	Insulin Nph Human Isophane	79	27
Metformin Hcl Er	Metformin Hcl	77	33
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	76	24
Trazodone Hcl	Trazodone Hcl	75	34
Finasteride	Finasteride	73	29
Duloxetine Hcl	Duloxetine Hcl	72	31
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	72	37
Escitalopram Oxalate	Escitalopram Oxalate	70	33
Allopurinol	Allopurinol	67	26
Pravastatin Sodium	Pravastatin Sodium	67	29
Furosemide	Furosemide	65	34
Pradaxa	Dabigatran Etexilate Mesylate	64	22
Mirtazapine	Mirtazapine	63	27
Pioglitazone Hcl	Pioglitazone Hcl	62	24
Famotidine	Famotidine	61	30
Albuterol Sulfate Hfa	Albuterol Sulfate	60	42
Carvedilol	Carvedilol	59	24
Spironolactone	Spironolactone	57	24
Ozempic	Semaglutide	56	12
Tramadol Hcl	Tramadol Hcl	54	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	51	21
Buspirone Hcl	Buspirone Hcl	50	16
Clopidogrel	Clopidogrel Bisulfate	50	21
Humulin R	Insulin Regular, Human	50	25
Lactulose	Lactulose	46	18
Fluticasone Propionate	Fluticasone Propionate	45	19
Sertraline Hcl	Sertraline Hcl	45	16
Wixela Inhub	Fluticasone Propion/Salmeterol	45	24
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	44	24
Montelukast Sodium	Montelukast Sodium	40	13
Arexvy	Rsvpref3 Antigen/As01e/Pf	39	39
Ezetimibe	Ezetimibe	34	16
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	34	20
Naproxen	Naproxen	33	24
Pregabalin	Pregabalin	33	18
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	32	18
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	31	31
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	29	suppressed
Spiriva Respimat	Tiotropium Bromide	29	suppressed
Fenofibrate	Fenofibrate	28	suppressed
Mupirocin	Mupirocin	28	15
Clonazepam	Clonazepam	27	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Metoprolol Succinate	Metoprolol Succinate	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Morphine Sulfate	Morphine Sulfate	22	suppressed
Clobetasol Propionate	Clobetasol Propionate	21	16
Ibandronate Sodium	Ibandronate Sodium	21	suppressed
Morphine Sulfate Er	Morphine Sulfate	21	suppressed
Glimepiride	Glimepiride	20	14
Alvesco	Ciclesonide	19	suppressed
Colchicine	Colchicine	19	11
Ondansetron Odt	Ondansetron	18	11
Terbinafine Hcl	Terbinafine Hcl	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Clonidine	Clonidine	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Breyna	Budesonide/Formoterol Fumarate	15	11
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Lovastatin	Lovastatin	15	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	15	14
Prednisone	Prednisone	15	15
Temazepam	Temazepam	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Victoza 2-Pak	Liraglutide	14	suppressed
Fluocinolone Acetonide	Fluocinolone Acetonide	13	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	12	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Estradiol	Estradiol	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	11	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error